Clinical trial
The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and…
NCT00483938 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00483938 |
|---|---|
| Title | The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE) |
| Official title | The Individualized Management With Pegasys and Ribavirin Offering Viral Eradication (IMPROVE) Trial |
| Acronym | IMPROVE |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | Pegylated-interferon Alfa-2a, Ribavirin |
| Enrollment | 236 |
| Start date | Jun 1, 2007 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Jun 8, 2007 |
| Last update posted | Jan 23, 2017 |
| Countries | Canada, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: